Imatinib Resistance and Other Diseases Targeted by Imatinib

This lecture from the iBioSeminars project is presented by Brian Druker of HHMI and the Oregon Health & Science University Cancer Institute. It describes how although the majority of patients with CML respond well to imatinib, a minority of patients have relapsed. This part of the lecture will cover what has been learned about mechanisms of relapse and how this information has been translated into new therapies for patients with imatinib resistance. Although imatinib is a relatively specific inhibitor of the ABL kinase, a couple of other kinases, KIT and the platelet derived growth factor receptor are also inhibited by imatinib. This use of this information to treat successfully treat other malignant diseases driven by these kinases will be reviewed. This video is the second of three, running 25:12 minutes and can be downloaded in QuickTime, MP4, M4V, or PDF formats. It can also be streamed on iTunes or YouTube.